Grifols reported EUR156.07M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Arca Biopharma USD 504K 246K Sep/2024
Bio Path 130K 95K Sep/2025
Capricor Therapeutics 3.05M 2.46M Dec/2025
Cara Therapeutics 39.02M 4.73M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Immunic 400K 400K Dec/2024
Infinity Pharmaceuticals USD 45K 0 Jun/2023
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
TherapeuticsMD USD 20K 25K Sep/2023